PPARA and metabolic dysfunction-associated steatotic liver disease: Saroglitazar is a novel PPAR-α/γ dual agonist has shown to reduce lipid levels (triglycerides and cholesterol), improve insulin sensitivity, reduce liver injury, inflammation and oxidative stress which ultimately reverse the fibrosis and overall improvement in NAFLD/NASH [5–8].